We probably should start to use the term “Somatostatin Receptor PET” (SSTR PET) a bit more. We got used to using the term Ga68 PET but since then we have an approved copper version known as 64Cu Dotatate (commercial brand name in US DETECTNET™). Now we have another in the clinical trial pipeline and will add others as they come onto my radar.
A Diagnostic Imaging Study of 64Cu-SARTATE™ Using Positron Emission Tomography (PET) on Patients With Known or Suspected NETs
Trial status: Recruiting
The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) NETs as a potential new way to help diagnose this type of cancer.
63 patient multicentre study run in Australia.
- Royal North Shore Hospital
- Peter MacCallum Cancer Centre
- Royal Adelaide Hospital
How does it compare to Ga68 Dotatate?
Site: Peter MacCallum Cancer Centre,
Principal Investigator: Prof Rod Hicks
In comparison to 68Ga-DOTATATE scans, 64Cu-SARTATETM imaging in participants with NETs was equivalent at 1 hour, and superior at 4 hours, allowing detection of additional tumours at later time points.
Read more about SARTATE here.
Theranostics. High late-retention in tumour and clearance from the liver suggests suitability for diagnostic studies as well as for prospective dosimetry for 67Cu-SARTATE PRRT (as at Apr 2021, being trialled with Neuroblastoma)
If you can see it, you can detect it. Read more about Neuroendocrine Neoplasms imaging.
Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.
Inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
- External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy
- Clinical Trial: Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana)
- Blog review and top 10 for 2021: RonnyAllan.NET
- Neuroendocrine Cancer Diarrhea- building the jigsaw: Bile Acid Malabsorption
- 177Lu-DOTA-LM3 – a novel radionuclide therapy proven safe and effective to treat neuroendocrine neoplasms (NEN)
Thanks for reading.
Sign up for my newsletters – Click Here